| Similar Articles |
|---|
 |
The Motley Fool
April 29, 2010
Brian Orelli |
Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business.   |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
Pharmaceutical Executive
September 1, 2006
Sarah Houlton |
Global Report: Break with Tradition Pharma's battle against animal-rights activists has been long-lasting and decidedly uphill. But now, with Prime Minister Tony Blair on its side, industry sees light at the end of the tunnel. |
The Motley Fool
May 1, 2008
Brian Lawler |
Glaxo's Global Growth Gambit The pharmaceutical's new CEO has changes in mind. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
March 31, 2010
Brian Orelli |
A Double-Digit Jump? For That? Isis' drug discovery license doesn't look too exciting to me. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
The Motley Fool
March 30, 2011
Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. |
The Motley Fool
January 21, 2010
Brian Orelli |
The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments. |
The Motley Fool
October 26, 2006
Brian Lawler |
Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth. |
The Motley Fool
December 17, 2008
Brian Orelli |
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. |
The Motley Fool
December 1, 2005
Brian Gorman |
Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note. |
The Motley Fool
February 22, 2010
Brian Orelli |
Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light. |
The Motley Fool
September 12, 2006
Brian Lawler |
Glaxo's Big Tax Bill The pharmaceutical finally decided to pay up and settle its long-running tax dispute with the IRS for $3.1 billion. |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
The Motley Fool
February 3, 2011
Owain Bennallack |
Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks. |
